W
WAVEMAN · COMPANY
KPTI · Karyopharm Therapeutics Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

KPTI

Karyopharm Therapeutics Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001503802
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$40.1K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
65
13F, latest reported quarter
REVENUE GROWTH
+0.6%
XBRL, annual
NET MARGIN
-134.2%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$40.1K over 180 days
-$1.4K over 90 days
more than 59% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
65 funds added or opened last quarter
more than 51% of Pharma & Biotech
REVENUE
+0.6% year over year
below 52% of Pharma & Biotech
MARGIN
-134.2% net margin
below 68% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
33.3% of shares outstanding short · 2.7 days to cover · settled 2026-07-31
the highest in Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$40.1K across 6 people in 180 days.
65 funds added or opened positions in the latest 13F quarter, of 99 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -73.6%
-73.6%12M
-74%-30%+14%+57%2025-092025-102025-122026-032026-052026-072026-09 2026-03-02 · Paulson Richard A. sold $116.3K2026-03-02 · Poulton Stuart sold $48.0K2026-03-02 · Rangwala Reshma sold $47.7K2026-03-02 · Cheng Sohanya Roshan sold $43.3K2026-03-02 · Mano Michael sold $33.2K2026-05-14 · Paulson Richard A. sold $20.9K2026-02-03 · Macomber Lori sold $10.2K2025-09-15 · Paulson Richard A. sold $8.1K2026-03-02 · Abate Kristin sold $5.3K2026-04-21 · Rangwala Reshma sold $4.0K2026-05-14 · Rangwala Reshma sold $3.9K2026-05-14 · Poulton Stuart sold $3.8K2026-02-17 · Poulton Stuart sold $3.3K2026-05-14 · Cheng Sohanya Roshan sold $3.1K2025-09-15 · Rangwala Reshma sold $2.6K2025-09-15 · Poulton Stuart sold $2.6K2026-05-14 · Mano Michael sold $2.5K2025-10-01 · Abate Kristin sold $2.3K2025-09-15 · Cheng Sohanya Roshan sold $2.1K2026-01-21 · Abate Kristin sold $1.6K2025-09-15 · Mano Michael sold $1.5K2026-07-28 · Poulton Stuart sold $1.3K2026-05-14 · Abate Kristin sold $5042026-01-28 · Abate Kristin sold $3522025-09-15 · Abate Kristin sold $1482025-09-03 · Abate Kristin sold $812026-09-01 · Abate Kristin sold $38
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $40.1K sold by insiders over 180 days, 65 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Karyopharm Therapeutics Inc. insiders sold a net $40.1K of stock across 157 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Abate Kristin
Chief Accounting Officer
SELL
2026-09-01
19.0
$38
Poulton Stuart
EVP, Chief Development Officer
SELL
2026-07-28
189.0
$1.3K
Poulton Stuart
EVP, Chief Development Officer
SELL
2026-05-14
403.0
$3.8K
Rangwala Reshma
EVP & Chief Medical Officer
SELL
2026-05-14
408.0
$3.9K
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
SELL
2026-05-14
324.0
$3.1K
157 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 152 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
1,917,354.0 sh
$18.7M
ADAGE CAPITAL PARTNERS GP, L.L.C.
1,521,322.0 sh
$14.9M
ACORN CAPITAL ADVISORS, LLC
1,518,113.0 sh
$14.8M
GOLDMAN SACHS GROUP INC
1,424,658.0 sh
$13.9M
BlackRock, Inc.
1,418,799.0 sh
$13.9M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Ultra-Small Company Fund
$277.8K POSITION · AS OF 2026-03-31
0.3%
T. Rowe Price Health Care ETF
$25.0K POSITION · AS OF 2026-03-31
0.1%
Ultra-Small Company Market Fund
$122.5K POSITION · AS OF 2026-03-31
0.1%
T. Rowe Price Small-Cap Value Fund, Inc.
$4.9M POSITION · AS OF 2026-03-31
0.1%
Nomura Healthcare Fund
$185.7K POSITION · AS OF 2026-03-31
0.0%
iShares Micro-Cap ETF
$237.7K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 37 registered trials, 8 still enrolling or running — a status change here is dated weeks before the press release
5
Phase 1
0 ACTIVE
18
Phase 2
4 ACTIVE
4
Phase 3
2 ACTIVE
1
Not applicable
0 ACTIVE
9
Multi-phase
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$2.3M
$2.1M
$1.7M
-86%
—
2024
$2.1M
$1.7M
$1.1M
-80%
—
2023
$2.6M
$35.7K
$1.2M
-75%
—
2022
$6.9M
$1.6M
$2.9M
-47%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$146.1M$145.2M$146.0M$157.1M
OPERATING INCOME$-90.7M$-119.4M$-129.5M$-142.2M
NET INCOME$-196.0M$-76.4M$-143.1M$-165.3M
EPS (DILUTED)-17.93-14.00-18.79-2.02
OPERATING CASH FLOW$-75.4M$-127.5M$-92.7M$-149.6M
CASH$60.5M$62.5M$52.2M$135.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →